Member Info for Merchantbanker

UK RTC commercialization outside the UK ££££££££££££££

Personally i expect today to be about distancing measures and restrictions rather than testing. But i feel the update on testing will follow very quickly.

The most important part of this is they appear to now be accepting that antibodies = immunity. If you read it it is clear that immunity is now assumed, and that they guidance will change if immunity is disproved.

That is a huge step in itself.

"Antibody tests to help determine if people have immunity to SARS-CoV-2"

More importantly - The Mologic tests also satisfies the criteria, plus it has the added triple antibodies. Mologic test is 100% accurate at 20 days, the requirement is 98%.

Perhaps UK RTC takes up public funded orders and Mologic can be made available through pharmacies for private sales?

http://www.omegadiagnostics.com/Products/COVID-19/VISITECT-COVID19MAG

Greater than 98% - which basically means you almost need to match UK RTC otherwise it's a no thank you. My take is this is part of tackling the criticisms about opening up the contract tenders, because it's ruling out many other tests which leaves them with one - UK RTC.

10% of the population back to normal is better than 0%. But it will increase every day. If these tests went on the shelf in boots everyone would want to take one even just to know one way or another, that is another plus point in sales confidence.

Abingdon health are the lead of the consortium. If they are selling we are selling as we are a supplier to the UK RTC.

What is clear and unsurprising is we as human beings do not have the discipline to beat this virus without the necessary medical strategy. There is a simple solution and the most effective solution is to break contact to stop transmission. But we can't do it. People are too selfish.
We need tests but we also need consequence. There are too many people that even if they knew they had it would be selfish and not isolate. Tests that feed an NHS app provide all the data needed to apply consequence in one way or another. We know the UK RTC are directly involved with this App.

It's amazing how many people i still speak to over the weekends (in a socially distance way of course) that do not take covid seriously, it's not serious or still think it's some kind of conspiracy to control us and just have a general lack of understanding about it.

I have spent some time looking at other covid stocks. With ODX being significantly above my average price now, in normal circumstances i wouldn't be averaging up.

However, my belief is still that there so so much more value in this covid stock than any other. Today is such a testament to that. We have already approved tests, one of which is a sure bet with UK Government and the others are highly competitive on price and quality. We are not tied to the management of covid of one country,. If the wealth of certain countries could buy themselves out of this with vaccines there are several others that sadly can't. Antibody testing will remain to test the efficacy of vaccines. To have the hedged portfolio we have is position A in terms of Covid stocks. So i don't feel the need to hedge my bets with other stocks despite averaging up because there is a hedge within ODX much better than can be achieved in the market.

The key for ODX as well is that sadly many countries will be well behind in the pecking order with vaccines. The mologic tests going out to ODX distribution of 75+ countries will keep sales coming in for a very long time.

djm1 - no i meant antigen tests!! ooops!

Vaccine looking positive, with immune response. This is another crucial sign of immunity. Vaccines and antibodies are co aligned. Antibody testing will only grow as vaccines come online. Herd immunity is where it is going.

It shows the importance of hedging your product portfolio with antigen and antibody tests. Vaccines could be here before the lateral flow antibody test. We have a product portfolio that will stand the test of time with this virus.

We could be seeing the start of the second real dip in the wider market which has been coming for some time. IMO there is a fantastic opportunity to ride a company like ODX right through the uncertainties in the wider market, and then hoover up cheap stocks around about March once testing is starting to get a stranglehold on Covid. ODX will be making serious money at a time when many companies will be in big trouble.

IMO over the next month or so the strongest Covid stocks will start to really come through, and the hanger oners that are desperately trying to enter the covid space will start to fall away.

ODX are incredibly position in both antibody and antigen markets. They have taken the time to get the right products and the right processes to make things happen. The best things take just a little more time to get right and that is exactly what we will see here.

Antibody testing will be a huge fanfare testing programme. Mologic could be about to leap to the head of the lateral flow antigen offerings. The UK RTC we have been told for some time are also at the centre of an NHSX testing App. It will all come together and ODX will be at the centre of it.

Top up in cheaper than i was expecting!! Thanks to those not interesting in making a fortune.

Of course the gov are not interested in other tests... they already have a gold standard test.

Mowzer - i can almost get over the second point with some honesty, as it may be that is the best that can be achieved and then to ask the question is it better than nothing? It's the first point that currently makes this uninvestable for me.

Anyway enjoy your weekends said my 2p worth. No desire for you guys to lose out, just genuine comments at a time that will be forgotten come Monday and i will leave it there.

Believe it or not some of the more challenging views can often have the most positive results on these kind of things. If everyone just asks whens it going to £3, £4, £5 what are you going to learn? There's no point asking about things people are already comfortable with. If i have these issues you can be sure others have. If they can be answered to a satisfactory level you might find further improved confidence.

Vegas - It is so childish and pathetic that you feel the need to comment on another board just because someone posts a view that you don't agree with on another, as my comments there have nothing to do with this BB. These boards are not cults they are there to discuss the company. I'll keep my comments on this stock here and my comments on that stock there which i am more than entitled to thanks. If you disagree with what i have said, find me the evidence to counter it and i will retract the comment, otherwise my comment is a valid comment to make whether you like it or not.

Mowzer, it wasn't a deramp, more a sarcastic comment, but i get your point. I can revisit my main observations and put them in question form if you prefer. Hopefully AS can put them to bed properly and our views can be aligned.

1) Affimers were launched in 2014 when you raised £10m to scale up production and commercial capabilities, yet they are yet to lead to a single commercial opportunity 6 years on. All of a sudden the single biggest commercial opportunity the industry has ever experienced comes along where every biotech/diagnostics company in the world are competing to solve the problem, yet we are led to believe Avacta are leading the world in providing a solution where others are struggling. Why is it different this time and where's the evidence Affimers work outside of the lab and can be used to provide the promised lateral flow tests?

Here's AS talking about billion dollar markets in 2014. Sound familiar? How much of that has he tapped into over the last 6 years?

https://www.drugtargetreview.com/news/1763/avacta-life-sciences-takes-55bn-antibody-market-launch-affimers/

2) Are you preparing investors for a disappointing performance on sensitivity?

AS has been talking about Specificity and not Sensitivity. Leads me to believe they have poor sensitivity. Do you want to be in a room knowing that everyone that was negative has been picked up but a few positives have been missed? Isn't it supposed to be about stopping the spread of the virus, detect and isolate? AS is trying to use maths to sell the opinion that this doesn't matter when testing the wider population on a regular basis. Don't worry if it's poor, buy more tests and test more....... This wont do, especially as an enabling test. A false positive (low specificity) does not risk passing the virus on whereas false negatives (low sensitivity) does. It is reliant on the acceptance that a low sensitive POC saliva tests is better than no POC tests at all, which may well be what we have to accept, but this is likely why it is considered to be a long way off as high sensitivity is important.

If you want to iron out time-wasters I would aim your comments at ones like below, rather than from those that want to challenge and understand the business.

"Q fur A.S.:

When we reach £5-£10/share do you think I should buy buy a sea front villa in Sitges near Barcelona or try Barbados ?"